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Genome-wide meta-analyses identifies novel taxane-induced
peripheral neuropathy-associated loci
Lara E. Sucheston-Campbella, Alyssa I. Clay-Gilmourc, William E. Barlowd,
G. Thomas Buddb, Daniel O. Stramg, Christopher A. Haimang, Xin Shengg,
Li Yani, Gary Zirpolii, Song Yaoi, Chen Jiangk,l, Kouros Owzark,l,
Dawn Hershmanj, Kathy S. Albainm, Daniel F. Hayesn, Halle C. Mooreb,
Timothy J. Hobdayc, James A. Stewarto, Abbas Rizvia, Claudine Isaacsf,
Muhammad Salimr, Jule R. Gralowe, Gabriel N. Hortobagyip,
Robert B. Livingstonq, Deanna L. Kroetzh and Christine B. Ambrosonei
Objective Taxane containing chemotherapy extends
survival for breast cancer patients. However, taxane-induced
peripheral neuropathy (TIPN) cannot be predicted, prevented
or effectively treated. Using genome-wide analyses, we
sought to identify common risk variants for TIPN.
Patients and methods Women with high-risk breast
cancer enrolled in SWOG 0221 were genotyped using the
Illumina 1M chip. Genome-wide analyses were performed in
relation to ≥grade 3 Common Terminology Criteria for
Adverse Events (CTCAE) neuropathy in European and
African Americans. Data were meta-analyzed with GW
associations of CTCAE ≥grade 3 versus <grade 3 in
CALGB 40101 assuming a fixed effects model.
Results The percentage of ≥grade 3 TIPN in 1269
European Americans and 139 African Americans in S0221,
was 11.6 and 22.3%, respectively. CALGB 40101 ≥grade 3
TOPN was 7.2%. The most significant association with
≥grade 3 TIPN was the G allele of rs1858826 in GNGT1
(Pmeta= 1.1× 10
− 7), which showed a decrease in risk of
≥grade 3 TIPN (odds ratio= 0.29, 95% confidence interval:
0.18–0.46).
Conclusion The genetic variants associated with ≥grade 3
TIPN are hypothesized to have biochemical functions and
reside in and near genes involved in diabetes and diabetic
neuropathy. This finding is consistent with results fromCALGB
40101 pathway analyses. Larger homogeneous trials with
similar dosing and criteria for defining neuropathy are needed
to properly assess the relationship of genomics with the
neuropathy spectrum. Pharmacogenetics and Genomics
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Introduction
Multidrug regimens for the treatment of breast cancer, par-
ticularly those including taxanes, have resulted in improved
survival for breast cancer patients [1–3]. However, these
drugs have both short-term and long-term effects that
profoundly impact function and quality of life. Importantly,
toxicities can also result in dose reduction or termination,
thus reducing treatment efficacy. Taxane-induced peripheral
neuropathy (TIPN), one of the most common side effects,
cannot be predicted, prevented or effectively treated,
and a substantial number of patients still experience grade
3 and 4 toxicities with symptoms lasting up to 2 years post-
treatment [4].
Predictive markers of TIPN could be clinically relevant for
prevention of this debilitating side effect. A number of
studies, reviewed in [5], have sought to determine the
underlying genetic susceptibility to TIPN [5–9], although
results have not been consistent. The goal of the present
study was to perform a meta-analyses of genome-wide
associations with NCI Common Toxicity Criteria for
Adverse Events (CTCAE) grade 3 and greater sensory
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neuropathies in two clinical trials, the North American
Breast Cancer Intergroup clinical trial led by SWOG
(S0221) and CALGB 40101. S0221 included 3294 women
with high-risk breast cancer registered to differing dose
and schedule of cyclophosphamide, anthracycline, and
taxane, with blood samples collected from 1874 patients
[10]. CALGB 40101 was a phase III randomized trial
comparing cyclophosphamide and doxorubicin versus
single-agent paclitaxel as adjuvant therapy for patients
with breast cancer who were at relatively low risk for
relapse [11].
Herein, we report on common genetic variants that confer
susceptibility to grade 3 or greater clinical neuropathy, as
well as those previously tested for association with neu-
ropathy outcomes following treatment with paclitaxel.
Patients and methods
Patients
S0221
Patients participating in the North American Breast Cancer
Intergroup clinical trial S0221 (NCT00070564) led by SWOG
comprise the patient population. In this trial, patients with
node-positive or high-risk node-negative operable breast
cancer first received treatment with one of three different
regimens of doxorubicin and cyclophosphamide (AC) and
then were randomly assigned to either a standard-dose treat-
ment of paclitaxel (T) given every 2 weeks for 12 weeks with
pegfilgrastim support, or a low-dose weekly regimen for
12 weeks. The premise of the trial was to test whether a
continuous ‘metronomic’ schedule (low-dose weekly regimen)
is superior to an accelerated but more conventional schedule
of AC–T for breast cancer [10].
To be eligible for the trial, patients must have had node-
positive or high-risk (tumor≥2 cm) node-negative operable
stage II or III invasive breast cancer with known estrogen
receptor/progesterone receptor status and no prior cancer,
have undergone breast surgery, and have had no prior
chemotherapy.
Specimen collection and DNA processing
All S0221 patients who participated in the substudy gave
written informed consent to have blood drawn for
germline genetic analysis. Blood was drawn into a 10-ml
purple top tube upon registration to S0221 and shipped
to the Roswell Park Cancer Institute Laboratory, where it
was processed and stored at − 80°C. For this study, DNA
was extracted from whole blood using Qiagen flexigene
Kit (Qiagen, Venlo, Netherlands) according to manu-
facturer’s protocol [8]. Genotyping was performed at the
University of Southern California using the Illumina
1M chip (Illumina; San Diego, California, USA).
Toxicities evaluated in S0221
Toxicities were monitored and reported using the CTCAE,
version 3.0, which contains descriptive terminology to be
used for adverse event reporting. Grade 3 toxicities
interfere with activities of daily living, and grade 4 adverse
events are life-threatening and often require hospitaliza-
tion. Required toxicity reporting for S0221 included only
those individuals experiencing grades 3 or 4. For each
individual, only themaximum toxicity experienced following
taxane treatment was reported. Because of the small number
of grade 4 sensory toxicities (<5), we consider ≥grade 3
CTCAE collectively.
Statistical analyses
Genotyping and quality control
A total of 1966 total samples were sent for genotyping,
including 44 replicate pairs (n=88) and nine hapmap CEU
trios (n=27). Samples were randomized to plates based on
toxicity reported (yes/no) and treatment arm [12]. Following
sample quality control, single-nucleotide polymorphisms
(SNPs) were removed if they could not be mapped to
current genome build, could not be called, there was evi-
dence of Mendelian or replicate errors, excess missingness
(>2%), minor allele frequency less than 1%, or if they were
out of Hardy–Weinberg equilibrium proportions at P value
less than 0.005 [separately tested in European Americans
(EA) and African American (AA) populations] [13]. Principal
components were constructed using a set of independent
SNPs in all patients self-declaring ‘Caucasian’ race and
‘Non-Hispanic’ ethnicity and mean values for the first
three eigenvectors within were determined [6]. To address
population heterogeneity, individuals with any of the first
three eigenvectors more than 2 SDs from each mean
value were excluded. This was repeated for all individuals
self-declaring ‘Black’ race and ‘Non-Hispanic’ ethnicity.
All quality control measures were implemented in Plink and
R statistical software (R Foundation for Statistical
Computing, Vienna, Austria) [14].
Imputation
Genotype data were imputed using Impute2, v2.0
[15,16]. A reference panel of haplotypes was constructed
using 1000 Genomes Phase 3 CEU and YRI data and
imputed SNP genotypes using all Illumina SNPs that
passed the previously described QC. Imputation results
were removed at info score threshold of less than 0.70,
certainty less than 0.70 and a minor allele frequency less
than 0.01 using QCTool [17].
Genome-wide analyses is S0221
Logistic regression models for each SNP, adjusted for age
and treatment arm, were used to calculate odds ratios (ORs)
and 95% confidence intervals (CIs) for the association of
each SNP with ≥grade 3 neuropathies. SNP P-values were
determined using likelihood ratio tests. Genomic inflation
factor was estimated for all analyses [18].
Power calculations for main effects in S0221
Calculations of risk that is detectable with 80% power were
performed considering allele frequency ranges between 10
and 50% and assuming frequency of neuropathy at ~ 12%.
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Applying Bonferroni’s correction for one million tests
(threshold of P= 5× 10−8) we are able to detect with more
than 80% power variants with ORs in the range of 2.45
down to 1.78 per copy of the risk allele assuming an
effected allele frequency between 10 and 50%, respec-
tively. This OR range is consistent with those found in the
published literature.
Genome-wide analyses in CALGB 40101
Cancer and Leukemia Group B trial 40101 (NCT00041119,
Alliance for Clinical Trials in Oncology) was conducted using
a phase III 2×2 factorial design to determine whether six
cycles of a chemotherapy regimen are superior to four cycles,
and whether paclitaxel is as efficacious as AC, but with
reduced toxicity [11]. Data were available 855 Northern
European and 117 AA patients with breast cancer who were
treated with taxanes typed at 521 600 SNPs using the
HumanHap610-Quad Genotyping BeadChip (Illumina, San
Diego, California, USA) [6]. Imputed data were not available
for analysis. Only specimens from patients enrolled in
CALGB 40101 who had signed a protocol-specific informed
consent for sample use, in accordance with federal and
institutional guidelines, were available for analysis. Although
these data have been analyzed for neuropathy associations
with cumulative dose and ordinal neuropathy grades [6], in
order for meta-analyses to be done on comparable pheno-
types across trials logistic regression was performed using
data from the 855 Northern European patients; 59 experi-
enced ≥grade 3 toxicity and 796 experienced <grade 3
toxicity. In AA patients, 103 experienced <grade 3 toxicity,
and 14 ≥grade 3 toxicity [6]. Regression models for each
SNP, adjusted for age and treatment arm, were used to
calculate ORs and 95% CIs for the association of each SNP
with ≥grade 3 neuropathies. SNP P-values were deter-
mined using likelihood ratio tests.
Meta-analyses of S0221 and CALGB 40101
Meta-analyses were performed using S0221 EA, S0221
AA and CALGB 40101 Northern Europeans. Because of
the small number of AA patients with ≥ grade 3 toxicity
in CALGB 40101 we did not include these results in the
meta-analyses. P-values for the three data sets were
combined using METAL software with weights propor-
tional to the sample size [19]. Regional association plots
of the most significant regions were constructed using
SNIPA [20].
Candidate gene analyses
More than 70 studies have been published testing asso-
ciations between genetic variation and neuropathy,
measured using CTCAE grades, FACT-TAX scores and/
or cumulative paclitaxel dose to event [5]. We tested
SNPs from these candidate studies, as well as those
presented in the CALGB 40101 genome-wide associa-
tion study Main and Supplementary results [6] and
ECOG analyses [9] for association with CTCAE ≥ grade
3 in S0221.
Results
Quality control
The Consort Flow diagram for S0221 (Supplementary
Fig. 1, Supplemental digital content 1, http://links.lww.
com/FPC/B286) shows details of the study schema for
patients for whom there were DNA and genotype data
available, as well as the results of the data cleaning and
quality control steps (details provided in Supplementary
Materials). Study design for both the meta-analyses and
tests of previous candidate SNP associations is shown in
Supplementary Fig. 2 (Supplemental digital content 2,
http://links.lww.com/FPC/B287). Following quality assur-
ance and control, 1269 EA (147 ≥ grade 3) and 139 AA
(31 ≥ grade 3) individuals with CTCAE grade informa-
tion were available for analysis. Patient characteristics are
summarized in Table 1. SNP quality control yielded a
total of 741 726 and 775 449, EA and AA typed SNPs,
respectively.
Genome-wide analyses with Common Terminology
Criteria for Adverse Events neuropathy ≥grade 3
The Manhattan and Q-Q plots of S0221 P-values are pro-
vided in Supplementary Figs 3 and 4 (Supplemental digital
content 3, http://links.lww.com/FPC/B288 and Supplemental
digital content 4, http://links.lww.com/FPC/B289), respectively.
Meta-analyses of the S0221 EA, S0221 AA and CALGB
40101 EA did not identify loci that display genome-wide
significant association with ≥grade 3 neuropathy. Table 2
shows the most significant meta-analysis associations with
≥grade 3 neuropathy. The most significant association was
the G allele in rs1858826, which correlates with a reduced
odds of ≥grade 3 (ORmeta=0.28; 95% CI: 0.12–0.55,
Pmeta=1.0×10
−7) and shows consistent evidence of asso-
ciation across S0221 EA (OR=0.21; 95% CI: 0.10–0.46,
P=8.2×10−7), S0221 AA (OR=0.26; 95% CI: 0.07–0.95,
P=0.04), and CALGB 40101 EA (OR=0.47, 95% CI:
0.20–1.09, P=0.07). The second most significant association,
the A allele in rs910920 in NXN, also correlates with
a reduced odds of ≥grade 3 (ORmeta=0.57; 95% CI:
0.45–0.73, Pmeta=4.9×10
−6). Regional association plots of
rs1858826 and rs910920 are shown in Supplementary Figs 5
and 6 (Supplemental digital content 5, http://links.lww.com/
FPC/B290 and Supplemental digital content 6, http://links.
lww.com/FPC/B293), respectively.
Previously reported neuropathy-associated single-
nucleotide polymorphisms
Results of these analyses by published candidate gene study
are shown in Supplementary Table 1 (Supplemental digital
content 7, http://links.lww.com/FPC/B291). Of the 209 unique
SNPs identified, 177 independent SNPs were tested for
association; 10 SNPs were in very strong linkage dis-
equilibrium with another candidate SNP (r2>0.9) and thus
were considered dependent and 22 were either not imputed
to a high degree of confidence (info score<0.7) or did not
have a proxy (r2>0.8) available for testing. Proxy SNPs
were defined as being in linkage disequilibrium, r2>0.8,
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with the candidate SNP in the 1000 Genomes Phase 3 CEU
as estimated using LDlink [21]. We report SNP ORs and
P-values for all CTCAE ≥grade 3 associations for both
S0221 EA and AA. The most significant candidate associa-
tion with grade 3+ neuropathy, rs3088050 (OR=1.6, 95%
CI: 1.2–2.1, P=0.0006, Padjusted=0.10), is a proxy SNP for
rs1966265, a coding variant in FGFR4. This variant was not
significant in either the ordinal or cox regression analyses in
CALGB 40101 [6].
Discussion
Defining sets of SNPs associated with neuropathy fol-
lowing taxane treatment could provide valuable biologi-
cal insight as to the causes of this side effect or potentially
be the first step in determining those at risk of neuro-
pathy. The assignment of alternative chemotherapeutic
regimens a priori, could thwart the decrease in quality of
life due to neuropathy experience, and also improve
treatment efficacy by avoiding dose reductions.
Therefore, we set out to identify and validate common
genetic variants that infer susceptibility to clinical neu-
ropathy in patients treated with taxanes for breast cancer.
We did not identify genome-wide significant (P<5×10−8)
SNPs associated with TIPN≥grade 3 versus<grade 3 in the
meta-analysis of S0221 and CALGB4010 [6]. Our strongest
associations on chromosomes 7 and 16 are hypothesized to
have biochemical functions and have been correlated with
genes involved in diabetes and diabetic neuropathy, a find-
ing consistent with CALGB 40101 pathway analyses [22].
ChiP-Seq experiments have shown hepatocyte nuclear factor
4α binds in the region containing rs1858826. This tran-
scription factor associates with gluconeogenesis and maturity
onset diabetes of the young, a metabolic and genetic disorder
that is a consequence of β-cell dysfunction. Furthermore, the
neuropathy-associated G allele occupies a very significant
position in the predicted motif MYBL1, which is hypothe-
sized to have a role in the proliferation and/or differentiation
of neurogenic, spermatogenic, and B-lymphoid cells [23,24].
Collectively, these data indicate that this SNP is likely to
affect transcription factor binding [25].
The A allele in the variant, rs910920, showed a reduction
in odds of neuropathy and is linked to a number of
biochemical functions. This variant has strong potential
to impact transcription factor binding, is a cis-eQTL
for VPS53 and the G allele (risk increasing) occupies a
prominent position in the (predicted) MEF2D motif, as
well as in BCL6 and MTF1 motifs [25]. The gene Ataxia
telangiectasia-mutated (ATM), which plays a role in
cellular responses to DNA damage, phosphorylates and
activates the MEF2D transcription factor, and knock-
downs of endogenous MEF2D in mice have been shown
to increase sensitivity to etoposide-induced DNA
damage and neuronal cell death [26]. BCL6, a master
transcription factor, has been hypothesized to regulate
LITAF [27], and mutations in the latter cause abnormal-
ities in protein degradation in Charcot–Marie–Tooth
disease type 1C, a demyelinating neuropathy disease
[28–30]. MTF1 is involved in DNA damage repair as it
induces expression of metallothioneins and other genes
involved in metal homeostasis in response to heavy
metals [31]. Furthermore, previous studies of diabetic
neuropathy in type 1 diabetes have found associated
SNPs in NXN, ∼ 68 kbp away from rs910920, but in
moderate linkage disequilibrium (r2= 0.65) and SNPs
within NXN also show genome-wide significant associa-
tions with type 2 diabetes [32,33].
The variant rs12202642 is a synonymous coding variant
in FGD2 and cis-eQTL for peptidase inhibitor 16, PI16,
in blood; rs1857798 is not linked to annotation data which
indicates any biochemical function [20].
Table 1 Characteristics of genotyped patients in S0221
Genetic and phenotypic information available
(N=1853) [n (%)]
After genomic and phenotypic quality control and imputation
(N=1408) [n (%)]
Patient characteristics ≥Grade 3 (N=215) <Grade 3 (N=1638) ≥Grade 3 (N=178) <Grade 3 (N=1230)
Arm
1 44 (13.3) 287 (86.7) 37 (14.7) 214 (85.3)
2 56 (15.6) 302 (84.4) 47 (18.3) 210 (81.7)
3 31 (8.2) 349 (91.8) 22 (7.9) 255 (92.1)
4 23 (6.6) 327 (93.4) 20 (7.4) 249 (92.6)
5 38 (17.9) 174 (82.0) 32 (18.1) 145 (81.9)
6 23 (10.4) 199 (89.6) 20 (11.3) 157 (88.7)
Self-reported racea
Caucasian, not Hispanic 155 (10.5) 1319 (89.5) 147 (11.6) 1122 (88.4)
Caucasian, Hispanic 11 (10.6) 93 (89.4) 0 0
Black, not Hispanic 33 (19.8) 134 (80.2) 31 (22.3) 108 (77.7)
Black, Hispanic 1 (33.3) 2 (66.6) 0 0
Asian 10 (14.7) 58 (85.3) 0 0
Native 1 (6.7) 14 (93.3) 0 0
Pacific Islander 3 (37.5) 5 (62.5) 0 0
Race unknown 2 (25) 6 (75) 0 0
BMI [mean (SD)] 30 (7.0) 31.4 (7.2) 32.71 (7.6) 30.7 (7.4)
Age [mean (SD)] 50.8 (10.7) 53.1 (9.7) 53.1 (9.7) 50.1 (10.3)
aRace groups do not sum to total because of small overlaps (<2) across groups.
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ZFPM2, a gene containing the most significant associa-
tion in the ordinal model for CALGB40101, which also
harbored some evidence of association with linked SNPs
in S0221 AA (Supplementary Table 1, Supplemental
digital content 7, http://links.lww.com/FPC/B291) contains
variants associated with coronary artery calcification in
AA [34]. A number of studies have demonstrated a rela-
tionship between cardiovascular diabetic neuropathy in
patients with both type 1 [35] and type 2 diabetes
[36–38]. In addition, this gene harbors variants associated
with circulating VEGF levels [39], which have been
associated with diabetes [40], diabetic neuropathy [41]
and protective effects on neuronal cells [42].
Chhibber et al. [22] recently demonstrated the idea that
common genetic pathways contribute to neuropathy.
Using GCTA analyses, the authors showed that the
heritable component of paclitaxel-induced neuropathy is
driven, in part, by genes involved in axon outgrowth.
They further hypothesized that disruption of axon out-
growth may be one of the mechanisms by which pacli-
taxel treatment results in sensory peripheral neuropathy
in susceptible patients. Although different mechanisms
cause neuron damage in diabetes and following paclitaxel
treatment, the Chhibber et al. [22] results, in conjunction
with gene expression analyses in mouse and human
studies of diabetic neuropathy, suggest that susceptibility
to sensory peripheral neuropathy is driven by the same
sets of genes [43]. Diabetes status was not made available
on S0221 patients. BMI between EA women experien-
cing CTCAE ≥ grade 3 neuropathy and those with
<grade 3 shows some evidence of significant difference
(P= 0.02). However, BMI was not significant in the
genetic association models (P>0.10), and there was no
evidence of effect modification or confounding by BMI.
This study is appropriately powered to detect clinically
relevant genetic effects and done clinical trial removes
potential random variation that arises in observational
studies. However, we do not have dates of neuropathy
onset or cumulative dosage, without this information, we
are not able to more sensitive analyses that could reveal
genetic susceptibility to neuropathy onset given drug
exposure. Larger studies on more diverse patient popu-
lations to validate, replicate, and discover variation related
to neuropathy are warranted.
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